I en poolet analyse af to fem- årige åbne forlængede studier (586 patienter i alt) var den kombinerede graft - og patientoverlevelsesrate ikke signifikant forskellige for basiliximab og placebo grupperne.
In a pooled analysis of two five-year open-label extension studies (586 patients total) the combined graft and patient survival rates were not statistically different for the basiliximab and placebo groups.